Current Report Filing (8-k)
15 October 2020 - 11:32PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): October 15, 2020
Akero
Therapeutics, Inc.
(Exact name of registrant as specified
in its charter)
Delaware
|
|
001-38944
|
|
81-5266573
|
(State or other jurisdiction
of
incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification
No.)
|
601 Gateway Boulevard, Suite 350
South San Francisco, CA
|
94080
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant’s telephone number,
including area code (650) 487-6488
Not Applicable
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b)
of the Act:
Title of each class
|
Trading
symbol(s)
|
Name of each exchange on which registered
|
Common Stock, par value $0.0001 per share
|
AKRO
|
The Nasdaq Global Select Market
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 8.01. Other Events.
The Company from time to time presents
and/or distributes to the investment community at various industry and other conferences slide presentations to provide updates
and summaries of its business. A copy of its current corporate slide presentation is being filed herewith as Exhibit 99.1 to this
Current Report on Form 8-K and is incorporated herein by reference. The Company undertakes no obligation to update, supplement
or amend the materials attached hereto as Exhibit 99.1.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: October 15, 2020
|
AKERO THERAPEUTICS, INC.
|
|
|
|
|
By:
|
/s/ Andrew Cheng
|
|
|
Andrew Cheng, M.D., Ph.D.
|
|
|
President and Chief Executive Officer
|
Akero Therapeutics (NASDAQ:AKRO)
Historical Stock Chart
From Apr 2024 to May 2024
Akero Therapeutics (NASDAQ:AKRO)
Historical Stock Chart
From May 2023 to May 2024